{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:42:44Z","timestamp":1794271364775,"version":"4.9.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the short-term efficacy and safety of efgartigimod versus intravenous immunoglobulin (IVIg) in patients with impending myasthenic crisis (IMC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center, randomized, open-label, prospective comparative cohort study included 38 acetylcholine receptor antibody\u2013positive (AChR\u2212Ab+) patients with IMC, which was defined as rapid progression of bulbar or respiratory symptoms within \u22642 weeks, meeting at least one of the following criteria:Myasthenia Gravis Foundation of America (MGFA) grade IVb, a Quantitative Myasthenia Gravis (QMG) bulbar subscore of 3, a respiratory subscore of 2, or a combined bulbar\u2013respiratory subscore \u22654. The participants were included and categorized into either the efgartigimod group (n=21; 10 mg\/kg weekly for 4 weeks) or the IVIg group (n=17; 400 mg\/kg\/day for 5 days). The primary endpoints were the rate of IMC remission within one month (defined as a QMG score &amp;lt;2 for both the bulbar and respiratory items, or a combined bulbar plus respiratory QMG score &amp;lt;4, or an improvement of the MGFA classification to below class IVb, sustained for at least 24 hours.) and time to remission. Secondary outcomes comprised changes in QMG total, bulbar, and respiratory subscores, and Myasthenia Gravis Activities of Daily Living (MG-ADL) from baseline to remission. Safety was assessed by rates of progression to myasthenic crisis (MC) and treatment-emergent adverse events (TEAEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between January 2024 and March 2025, 38 patients were randomized. IMC remission rates were 90.48% with efgartigimod and 94.12% with IVIg (P = 1.000). The median time to remission was significantly shorter with efgartigimod (8 days; 95% CI: 5.75\u201310.67) than with IVIg (12 days; 95% CI: 9.92\u201313.20; P = 0.009). One patient per group progressed to myasthenic crisis (4.76% vs 5.88%). No TEAEs were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Efgartigimod demonstrated comparable efficacy to IVIg for IMC remission but with a significantly faster onset, supporting its role as a rapid and safe alternative.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1760953","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:47:05Z","timestamp":1773298025000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of efgartigimod in the treatment of impending myasthenic crisis"],"prefix":"10.3389","volume":"17","author":[{"given":"Ning","family":"Li","sequence":"first","affiliation":[{"name":"Department of Neurology, General Hospital of Ningxia Medical University","place":["Yinchuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, General Hospital of Ningxia Medical University","place":["Yinchuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurology, General Hospital of Ningxia Medical University","place":["Yinchuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanzi","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Neurology, General Hospital of Ningxia Medical University","place":["Yinchuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Neurology, General Hospital of Ningxia Medical University","place":["Yinchuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhui","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Neurology, General Hospital of Ningxia Medical University","place":["Yinchuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yating","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurology, General Hospital of Ningxia Medical University","place":["Yinchuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boya","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Neurology, General Hospital of Ningxia Medical University","place":["Yinchuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Peng","sequence":"additional","affiliation":[{"name":"First Clinical Medical College, Ningxia Medical University","place":["Yinchuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Neurology, General Hospital of Ningxia Medical University","place":["Yinchuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neuroscience Intensive Care Unit (NCU), General Hospital of Ningxia Medical University","place":["Yinchuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Neurology, General Hospital of Ningxia Medical University","place":["Yinchuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/mus.27832","article-title":"Myasthenic crisis","volume":"68","author":"Claytor","year":"2023","journal-title":"Muscle Nerve"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: Executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"B4","article-title":"Expert consensus on the management of impending myasthenic crisis (2024)","volume":"32","author":"Sushan","year":"2024","journal-title":"Chin J Clin Neurosci"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/mus.10095","article-title":"Crisis\u201d in myasthenia gravis: An historical perspective","volume":"26","author":"Keesey","year":"2002","journal-title":"Muscle Nerve"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.3390\/biomedicines11123180","article-title":"Plasma exchange versus intravenous immunoglobulin in worsening myasthenia gravis: A systematic review and Meta-Analysis with special attention to faster relapse control","volume":"11","author":"Pavlekovics","year":"2023","journal-title":"Biomedicines"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27922","article-title":"Updated consensus statement: Intravenous immunoglobulin in the treatment of neuromuscular disorders report of the AANEM ad hoc committee","volume":"68","author":"Tavee","year":"2023","journal-title":"Muscle Nerve"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.68895","article-title":"Comparative analysis of intravenous immunoglobulins (IVIg) vs plasmapheresis (PLEX) in the management of myasthenic crisis","volume":"16","author":"Zain","year":"2024","journal-title":"Cureus"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16098","article-title":"Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: Post hoc analyses of the phase 3 pivotalADAPT study","volume":"31","author":"Bril","year":"2024","journal-title":"Eur J Neurol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2025.e00730","article-title":"Efficacy and safety of efgartigimod versus intravenous immunoglobulin in early intervention of acetylcholine receptor antibody-positive impending myasthenic crisis: A retrospective cohort study","volume":"22","author":"Guo","year":"2025","journal-title":"Neurotherapeutics"},{"key":"B13","doi-asserted-by":"publisher","first-page":"578431","DOI":"10.1016\/j.jneuroim.2024.578431","article-title":"Efgartigimod as a fast-acting add-on therapy in manifest and impending myasthenic crisis: A single-center case series","volume":"395","author":"Hong","year":"2024","journal-title":"J Neuroimmunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"28394","DOI":"10.1038\/s41598-024-79918-7","article-title":"Efgartigimod versus intravenous immunoglobulin in the treatment of patients with impending myasthenic crisis","volume":"14","author":"Ma","year":"2024","journal-title":"Sci Rep"},{"key":"B15","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1007\/s00415-025-13367-8","article-title":"Factors associated with early response to efgartigimod in patients with generalized myasthenia gravis: A multicenter retrospective observational study","volume":"272","author":"Zhu","year":"2025","journal-title":"J Neurol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: Subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): A multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2007.04.045","article-title":"Myasthenic crisis: Guidelines for prevention and treatment","volume":"261","author":"Jani-Acsadi","year":"2007","journal-title":"J Neurol Sci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.50901","article-title":"Clinical outcome measures following plasma exchange for MG exacerbation","volume":"6","author":"Raja","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12217","article-title":"Myasthenia gravis: An update for the clinician","volume":"175","author":"Sieb","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2019.07.006","article-title":"Heterogeneity and shifts in distribution of muscle weakness in myasthenia gravis","volume":"29","author":"de Meel","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2024.09.006","article-title":"New treatment strategies in Myasthenia gravis","volume":"180","author":"Attarian","year":"2024","journal-title":"Rev Neurol (Paris)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nri2155","article-title":"FcRn: The neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jns.2013.10.043","article-title":"Maintenance IVIg therapy in myasthenia gravis does not affect disease activity","volume":"338","author":"Hellmann","year":"2014","journal-title":"J Neurol Sci"},{"key":"B25","doi-asserted-by":"publisher","first-page":"51366552","DOI":"10.1177\/17562864251319656","article-title":"Patterns and predictors of therapeutic response to efgartigimod in acetylcholine receptor-antibody generalized myasthenia gravis subtypes","volume":"18","author":"Jin","year":"2025","journal-title":"Ther Adv Neurol Disord"},{"key":"B26","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12974-022-02448-4","article-title":"Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients","volume":"19","author":"Nelke","year":"2022","journal-title":"J Neuroinflamm"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1510992","article-title":"A real-world pharmacovigilance study of efgartigimod alfa in the FDA adverse event reporting system database","volume":"16","author":"Yang","year":"2025","journal-title":"Front Pharmacol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2022.2057223","article-title":"Immunomodulatory effects and clinical benefits of intravenous immunoglobulin in myasthenia gravis","volume":"22","author":"Dalakas","year":"2022","journal-title":"Expert Rev Neurother"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1760953\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:47:06Z","timestamp":1773298026000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1760953\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":28,"alternative-id":["10.3389\/fimmu.2026.1760953"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1760953","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fimmu.2026.1760953.s001","asserted-by":"subject"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"article-number":"1760953"}}